4583 On Other Exchanges
Symbol
Exchange
4583 is not on other exchanges.

chiome bioscience inc (4583) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIOME BIOSCIENCE INC (4583)

Related News

No related news articles were found.

chiome bioscience inc (4583) Related Businessweek News

No Related Businessweek News Found

chiome bioscience inc (4583) Details

Chiome Bioscience Inc. is engaged in the research and development of drug discovery platform technology worldwide. It helps drug discovery companies, such as drug manufacturers and biotech companies to develop antibody drugs through programs based on the autonomously diversifying library system (ADLib system). The ADLib system is a monoclonal antibody generating system that provides various arrays of antibodies in vitro, without using immunization. The company develops the ADLib system to generate therapeutics antibodies; and licenses novel therapeutic antibodies for antigens to pharmaceutical manufactures. Chiome Bioscience Inc. was founded in 2005 and is headquartered in Tokyo, Japan.

Founded in 2005

chiome bioscience inc (4583) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

chiome bioscience inc
Chiome Bioscience Inc. Reports Non-Consolidated Financial Results for the Nine Months Ended September 30, 2016

Chiome Bioscience Inc. reports non-consolidated financial results for the nine months ended September 30, 2016. For the period, the company's net sales were JPY 175 million against JPY 216 million for the same period a year ago. Operating loss was JPY 827 million against JPY 936 million for the same period a year ago. Ordinary loss was JPY 827 million against JPY 920 million for the same period a year ago. Loss before income taxes was JPY 962.138 million against JPY 948.854 million for the same period a year ago. Net loss was JPY 964 million against JPY 949 million for the same period a year ago. Net loss per Share was JPY 43.24 against JPY 43.18 a year ago.

Chiome Bioscience Inc. to Report Q3, 2016 Results on Nov 14, 2016

Chiome Bioscience Inc. announced that they will report Q3, 2016 results on Nov 14, 2016

Chiome Bioscience Inc. Presents at BIO Europe 2016 Conference, Nov-07-2016

Chiome Bioscience Inc. Presents at BIO Europe 2016 Conference, Nov-07-2016 . Venue: KoelnMesse - Congress Center North, Cologne, Germany.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4583 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4583.
View Industry Companies
 

Industry Analysis

4583

Industry Average

Valuation 4583 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHIOME BIOSCIENCE INC, please visit www.chiome.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.